| Dear Fellow Investor, Goldman Sachs thinks these stocks can go up 60% or more - Activision Blizzard, Inc.. – SYM: ATVI
Recent Price: $58.59
Price Target: $111
Firms with Buy Rating: Goldman Sachs, Truist Financial, Jefferies, and more.
Description: Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
========BREAKING======== Calendar Alert Up 37% Yesterday
Don't worry if you missed our "calendar alert" on the $2 biotech that jumped 37% yesterday.  We've just released another alert that can hand you a potential 187% gain in the next 60 - 90 days. ===============================
Alibaba Group Holding Limited – SYM: BABA
Recent Price: $124.06
Price Target: $213.50
Firms with Buy Rating: Goldman Sachs, J.P. Morgan, Raymond James, and more.
Description: Alibaba Group Holding Limited, through its subsidiaries, provides technology infrastructure and marketing reach to merchants, brands, retailers, and other businesses to engage with their users and customers in the People's Republic of China and internationally. It operates through four segments: Core Commerce, Cloud Computing, Digital Media and Entertainment, and Innovation Initiatives and Others. The company operates Taobao Marketplace, a social commerce platform; Tmall, a third-party online and mobile commerce platform for brands and retailers; Alimama, a monetization platform; 1688.com and Alibaba.com, which are online wholesale marketplaces; AliExpress, a retail marketplace; Lazada, Trendyol, and Daraz that are e-commerce platforms; and Tmall Global and Kaola, which are import e-commerce platforms. It also operates Lingshoutong that connects FMCG manufacturers and their distributors to small retailers; Cainiao Network logistic services platform; Ele.me, an on-demand delivery and local services platform; Koubei, a restaurant and local services guide platform; and Fliggy, an online travel platform. In addition, the company offers pay-for-performance, in-feed, and display marketing services; and Taobao Ad Network and Exchange, a real-time online bidding marketing exchange. Further, it provides elastic computing, database, storage, virtualization network, large-scale computing, security, management and application, big data analytics, machine learning platform, and Internet of Things services. Additionally, the company operates Youku, an online video platform; Alibaba Pictures and other content platforms that provide online videos, films, live events, news feeds, literature, music, and others; Amap, a mobile digital map, navigation, and real-time traffic information app; DingTalk, a business efficiency app; and Tmall Genie, an AI-enabled smart speaker. The company was incorporated in 1999 and is based in Hangzhou, the People's Republic of China
---Urgent Trade Alert: $1 Robotics Firm---
We just issued a brand new "buy alert" for a unique PRE-IPO stock... ... Backed by a $120 Million DARPA grant, Jeff Bezos, and Bill Gates. And it’s selling at just $1/share! There may only be 7 days left to get in so click here now. ====
Vertex Pharmaceuticals Incorporated – SYM: VRTX
Recent Price: $203.54
Price Target: $326
Firms with Buy Rating: Goldman Sachs, J.P. Morgan, Oppenheimer, and more.
Description: Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; Mammoth Biosciences; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Dylan Jovine
CEO & Founder,
Behind the Markets
www.behindthemarkets.com Behind The Markets is brought to you by Behind The Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 1-866-286-9356. Behind the Markets is brought to you by Behind the Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 1-866-286-9356. Behind the Markets is a newsletter offered to the public on a subscription basis. While subscribers receive the benefit of Behind the Markets opinions, none of the information contained therein constitutes a recommendation from Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Behind the Markets may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Behind the Markets’ past results are not necessarily indicative of future performance.
Employees of Behind the Markets are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE.
Behind the Markets’ Newsletter contains Behind the Markets’ own opinions, and none of the information contained therein constitutes a recommendation by Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.
You further understand that Behind the Markets will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter.
To the extent any of the information contained in Behind the Markets Newsletter may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
Behind the Markets’ past results are not necessarily indicative of future performance. DO NOT EMAIL Behind the Markets SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE.
The Editor's personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter.
Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance.
No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer.
To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.
The Newsletter's commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time
without notice.
The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information.
The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Behind the Markets
Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. |
Tidak ada komentar:
Posting Komentar